High drug prices are sure to come up again. So is Obamacare.
President Donald Trump's pick to lead the U.S. Health and Human Services Department is likely to face questions on those subjects and others when he faces senators at his second hearing on Capitol Hill on Tuesday.
Until about a year ago, nominee Alex Azar was an executive at drugmaker Eli Lilly & Co., a role that's fueled lawmakers' concerns that he might not be willing to take a tough stance against the pharmaceutical industry on drug prices. Azar told senators at a November hearing that he wants to end "gaming" by drugmakers that allows them to extend monopolies and keep prices high, an idea backed by both Republicans and Democrats.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
